Novel bridged cyclic compounds as histone deacetylase inhibitors

A compound of formula (I),

• their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof;
• wherein:
• Ar represents substituted or unsubstituted group selected from the group consisting of:
• aryl and heteroaryl;
• R1 represents substituted or unsubstituted group selected from adamantyl, adamantylalkyl, adamantylalkylidene, aza-adamantyl, homoaza-adamantyl, noradamantyl, noradamantylalkyl, homoadamantyl, heteroadamantyl and
• R2 represents substituted or unsubstituted group selected from the group consisting of:
• —OR5, ortho substituted aniline, amino aryl and amino heteroaryl;
• wherein R5 represents hydrogen, a substituted or unsubstituted group selected from:
• aryl, and heterocyclyl, or —COR6;
• wherein:
• R6 represents a substituted or unsubstituted group selected from:
• alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl;
• Z represents substituted or unsubstituted groups selected from alkylene and alkenyl having 1-6 carbon atoms;
• X represents —NR3—, —O—, —S—, —SO—, —SO2—, —NR3—CO— or —CO—NR3—;
• W represents O, S or NR4;
• Y represents a bond, —NR4—, —O—, —S—, —SO— or —SO2—;
• R3, R4 and R7 represent hydrogen or substituted or unsubstituted group selected from the group consisting of:
• alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl;
• or R3 and R4, combine together to form a ring which is optionally substituted by the group selected from oxo, thioxo and —C═NR7;
• 1 is an integer selected from 0-1;
• n is an integer selected from 0-1;
• m is an integer selected from 0-1;
• o is an integer selected from 1-4;
• and p is an integer selected from 0-1, with a proviso that when p=0, R2 is other than OR5.